Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Julphar
Colorcon
Cerilliant
US Department of Justice
Queensland Health
UBS
Farmers Insurance
Baxter

Generated: April 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,394,406

« Back to Dashboard

Which drugs does patent 8,394,406 protect, and when does it expire?

Patent 8,394,406 protects ORACEA and is included in one NDA.

This patent has twelve patent family members in seven countries.
Summary for Patent: 8,394,406
Title:Once daily formulations of tetracyclines
Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
Inventor(s): Chang; Rong-Kun (Rockville, MD), Raoufinia; Arash (Springfield, VA), Shah; Niraj (Owings Mills, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/926,934
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use; Process;

Drugs Protected by US Patent 8,394,406

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp ORACEA doxycycline CAPSULE;ORAL 050805-001 May 26, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,394,406

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,394,405 Once daily formulations of tetracyclines ➤ Try a Free Trial
8,470,364 Once daily formulations of tetracyclines ➤ Try a Free Trial
7,749,532 Once daily formulations of tetracyclines ➤ Try a Free Trial
8,709,478 Once daily formulations of tetracyclines ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,394,406

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1615622 ➤ Try a Free Trial
Portugal 2204168 ➤ Try a Free Trial
Japan 2012144554 ➤ Try a Free Trial
Japan 5622773 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cipla
Medtronic
Chubb
Argus Health
UBS
Daiichi Sankyo
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.